1. Introduction {#s0005}
===============

Respiratory tract infection, especially *Pneumocystis pneumonia* (PCP), is a significant causative agent of fatal diseases ([@b0045]). The organism *Pneumocystis Jirovecii* previously known as *Pneumocystis carinii*, is the causative agent of *Pneumocystis Jirovecii* pneumonia ([@b0080]). In developed countries, the rate of *Pneumocystis Jirovecii* pneumonia co-infection with HIV has reduced while controlling the prevalence of co-infection in developing countries remains challenging ([@b0095]). Many factors can make PCP diagnosis tricky such as nonspecific symptoms, coexistence of other infections, and difficulty in establishing a reliable culturing system of this pathogen ([@b0060]). Rapid and accurate identification of infections and suitable recommended treatment, which is based on accurate microbiological results, is still required; however, the current standard clinical tests lack high sensitivity and flexibility ([@b0045]).

The standard direct microscopic characterization of *Pneumocystis Jirovecii* from different samples such as bronchoalveolar lavage (BAL), lung biopsy, or induced sputum is the hallmark method for diagnosis ([@b0060]). Gomorimethanamine silver staining (GMSS) is considered the more sensitive immunofluorescence assay for microscopic detection of the lower respiratory system samples ([@b0065]). However, molecular methods such as PCR have much higher sensitivity than microscopic identification ([@b0060]; Arcenas et al., 2006). Different PCR platforms, patient populations, and different specimen types have been extensively clarified ([@b0060]; Arcenas et al., 2006). Real-time (RT-PCR) is ideal for standard microscopic techniques as PCR utilizes a closed system which minimizes contamination and offers the cycle thresholds function, which helps to detect the real infection instead of airway colonization (Arcenas et al., 2006; [@b0055]).

BAL and sputum are ideal samples for detecting the nucleic acids of *Pneumocystis* using RT-PCR, and the results are more sensitive than microscopic identification ([@b0060]). However, RT-PCR allows accurate and specific quantification of DNA. Moreover, RT-PCR has the potential ability to discriminate between asymptomatic carriage of *Pneumocystis Jirovecii* and clinical disease based on the load of pathogen copies ([@b0050]). There is a need for an alternate method for rapid and accurate laboratory techniques in order to diagnose the disease in limited resources countries and prescribe appropriate medication. Hence, our main objectives were to study the incidence of PCP among patients with respiratory problems, and to compare QRT- PCR with various diagnostic methodologies.

2. Methodology {#s0010}
==============

2.1. Study population and design {#s0015}
--------------------------------

The sample size was calculated by using n = Zα^2^ (p × q)/d^2^ formula based on prevalence 30.3% ([@b0005]). A total of 100 suspected cases for PCP, which met the essential medical manifestations, radiological criteria, and microbiological findings, from tertiary care hospitals in the period between January 2019 and August 2019, were included into this study. Patients with common respiratory symptoms such as shortness of breath, cough, chest pain, and typical interstitial pulmonary infiltrates in X-ray, or computed tomography scan were enrolled. The clinical data and medical history of the patients were documented. BAL samples were collected using 0.9% sodium chloride solution and instantly sent to the laboratory for the required analysis.

2.2. Ethics approval {#s0020}
--------------------

The study obtained ethical approval from the Research Ethics Committee, Deanship of Scientific Research, King Khalid University, Abha, Kingdom of Saudi Arabia with vide approval number is (ECM-2019-73) - (HAPO-06-B-001).

2.3. Pneumocystis RT-PCR {#s0025}
------------------------

Isolation and purification of *Pneumocystis Jirovecii* DNA from BAL sample was done by using QIAamp DNA Mini Kit manufactured by Qiagen (Germany). Pneumocystis RT-PCR assay was done by using MycAssay Pneumocystis kit, manufactured by Myconostica (UK). The assay was designed to detect the mitochondrial ribosomal large subunit (mLSU). MycAssay kit is a commercial qualitative real-time PCR technique that utilizes molecular beacons for *Pneumocystis Jirovecii* pneumonia detection. The assay kit includes an internal amplification control (IAC) sequence and DNA fragment leading to confirmed amplification as *Pneumocystis Jirovecii* lack both IAC and DNA fragment.

The target sequence of *Pneumocystis Jirovecii* pneumonia is labeled with a 6-carboxyfluorescein (FAM) beacon, while the IAC sequence is labeled with a HEX beacon. The fluorescence emitted by each beacon was monitored using CFX96 touch real-time PCR system. In this method, the negative cut-off value of cycle threshold (CT) of 39 was used as per manufacturer's instruction. A CT value lower than this was considered positive ([@b0085]). The semiquantitative manner was used to interpret CT values, which explains the correlation between fungal burden and CT values (Hauser et al., 2011).

2.4. Merifluor DFA immunofluorescence testing {#s0030}
---------------------------------------------

The reference diagnostic test was Immunofluorescent staining (IFAT) using Merifluor DFA immunofluorescence test, according to the manufacturer\'s instructions (Meridian Bioscience, Inc., Cincinnati, Ohio).

2.5. Standard diagnostic tests {#s0035}
------------------------------

Special staining diagnostic techniques, including Gomorimethanamine silver staining (GMSS), Giemsa staining, and Toludine blue O (TBO), were used. Both trophozoite forms and cyst can be detected by using Giemsa staining, while TBO detects the cyst form only.

The results of Pneumocystis RT-PCR were compared with GMSS, TBO, and Giemsa staining results. We have shown that IFAT positive cases responded to treatment. Moreover, all cases, which were positive by other staining techniques, were IFAT positive. Therefore, in our study, the other techniques were compared to IFAT, as it is considered a standard gold method. The specimens were reported truly positive for *Pneumocystis Jirovecii* if the pathogen was detected by any of the previously mentioned methods accompanying with clinical presentations of *Pneumocystis Jirovecii*.

2.6. Statistical analysis {#s0040}
-------------------------

Means and standard deviations (SD) were calculated for participants' age, and frequencies were calculated for gender and test results. The sensitivity, positive and negative predictive values, and specificity were calculated using the Statistical Package for the Social Sciences (version 17.0; SPSS S.L., Madrid, Spain). The significance level was set at p ≤ 0.05.

3. Results {#s0045}
==========

The diagnostic examination of *Pneumocystis Jirovecii* from BAL was performed on 100 patients. The patients' mean age was 52 (SD ± 16) years ranged from 16 to 78 years. 41% were female, and 59% of the patients were male. Thirty-five patients were positive for *Pneumocystis Jirovecii* in our study by using several detection methods.

As shown in [Table 1](#t0005){ref-type="table"}, cough (100%), fever (92%), weight loss (80%), and dyspnea (76%) night sweats (54%) were the most common clinical manifestations. Crepts and wheezing were seen in 62% and 75% PCP patients, respectively. Chest X-ray showed pulmonary infiltrates, which was the most common finding.Table 1Chest X-ray findings of PCP respiratory patients.S.No.Chest X-Ray findingsNumberPercentage (35)1Central Perihilarinfilterates1954.282Patchy infiltrates822.863Consolidation38.574Hilar Lymphadenopathy38.575Pneumothorax12.866Pleural effusion12.86

Generally, out of 100 specimens, 35 were positive, whereas 65 of 100 specimens were negative. 35 of 35 (100%) of positive specimens were detected by IFAT stain, 15 of 35 (42.86%) by GMSS, 8 of 35 (17.6%) by Giemsa stain, and 1 of 35 (2.8%) was detected by TBO stains. RT-PCR showed that 39 (39%) of patients were found to be positive for PCP. 35 of the 39 patients were positive IFAT (89.74%); the IFAT of 4 patients was either negative or undefined ([Fig. 1](#f0005){ref-type="fig"}). All 39 patients (100%) showed the clinical symptoms of *Pneumocystis Jirovecii* pneumonia.Fig. 1Comparison of different techniques among respiratory PCP patients.

The calculation of positive predictive values (PPV), sensitivity, disease prevalence (95% CI), negative predictive values (NPV), and specificity is shown in [Table 2](#t0010){ref-type="table"}. Sensitivity and specificity values are showed RT-PCR ([Fig. 2](#f0010){ref-type="fig"}) to be the best method, followed by IFAT, GMSS, Giemsa, and TBO methods. Positive sample amplification as shown in [Fig. 2](#f0010){ref-type="fig"} representing the positive amplification of *Pneumocystis jiroveci* infected patients and negative sample did not showed any amplification. The disease prevalence value for PCP positive cases ranged from 25.73% to 45.18% at 95% confidence interval (95% CI). [Fig. 3](#f0015){ref-type="fig"}, [Fig. 4](#f0020){ref-type="fig"} showed the cysts forms of *Pneumocystis jiroveci* stained with IFAT and GMSS, respectively. [Fig. 3](#f0015){ref-type="fig"} showed immunoflorescence of antibody used against *Pneumocystis jiroveci* in infected patients.Table 2Statistical parameters of different techniques positive for *Pneumocystis Jirovecii* pneumonia.No.TechniquesNumber of positive casesSensitivity (%)Specificity (%)PPV (%)NPV (%)95% CI1IFAT35100.00100.00100.00100.0025.73--45.182GMSS1542.86100.00100.0076.473Giemsa0822.8698.4688.8970.334TBO0102.8696.9233.3364.955RT-PCR39100.0093.8589.74100.00Fig. 2Real time PCR amplification for Pneumocystisjiroveci positive patients.Fig. 3Pneumocysiisjiroveci stained with IFAT seen in BAL sample.Fig. 4Pneumocystisjiroveci stained with GMSS in BAL sample.

4. Discussion {#s0050}
=============

Carlos Chagas discovered *Pneumocystis Jirovecii* in 1909, while investigating interstitial pneumonitis in Brazilian railroad workers ([@b0015]), but he misinterpreted the diagnosis and classified it as *Trypanosoma cruzi*. Previously *Pneumocystis Jiroveci* considered to be a protozoa and taxonomically has been a matter of controversy. Currently, the new studies have reclassified the *Pneumocystis Jirovecii* as an ascomycete fungus ([@b0095]). The pleomorphic trophozoite form and the cystic stage are major developmental stages of *Pneumocystis Jirovecii.* ([@b0095]). Colonization of *Pneumocystis Jirovecii* has been described in adult patients with chronic obstructive airway disease, making them reservoir for the infection ([@b0040]). In our study, clinical symptoms and findings like cough (100%), fever (92%), unintentional weight loss (80%), dyspnea (76%) were associated with risk of PCP similar to which has been seen in studies conducted in the United States ([@b0110]). In chest X-ray findings, 30/35 (85.7%) patients of PCP positive patients had typical interstitial pulmonary infiltrates consistently similar to the study which reported that pulmonary infiltrates present in 17 out of 19 (89.5%) patients, with 16 out of 19 (84.2%) patients presenting bilateral pulmonary infiltrates ([@b0020]).

In our study, we enrolled 100 patients with atypical pneumonia, 35% of patients were positive for *Pneumocystis Jirovecii.* PCP was detected using IFAT in all the 35 specimens, 15 of 35 (42.9%) were detected by GMSS, 8 of 35 (17.6%) by Giemsa stain, and 1 of 35 (2.8%) was detected by TBO stains. Nowadays, PCR for detection of Pneumocystis, especially Real Time-PCR, is commonly used in diagnosing PCP ([@b0080]). Our study showed excellent sensitivity (100%) and strong NPV (100%) for RT-PCR, which were also confirmed by several other studies ([@b0010], [@b0030]).

In most studies that compared PCR methods with microscopy for PCP diagnosis, PCR exhibited better sensitivity for *Pneumocystis Jirovecii* detection in patients with chronic lung disease ([@b0070]). Meta-analysis showed a very high accuracy of PCR in BAL samples for the diagnosis of *Pneumocystis Jirovecii* in patients who are at risk and a pooled sensitivity of 98.3% and a specificity of 91.0% ([@b0070], [@b0025]). The specificity and sensitivity of nested-PCR were 93% and 100%, respectively ([@b0070]). Moreover, the quick and reliable detection of the organism using the PCR test remains an advantage ([@b0105]).

Our RT-PCR showed that 39 (39%) patients were found to be positive for PCP. Thirty-five of these patients had a positive IFAT (89.74%), with negative or undefined IFAT in 4 (10.26%) samples. The probable reason for this over diagnosis might be due to the fact that PCR does not discriminate between pneumocystis colonization and infection as this highly sensitive method detects pneumocystis DNA regardless of the clinical presentation ([@b0115]). Therefore, this differentiation remains the most relevant clinical issue.

Contamination in PCR and the lack of a suitable culturing system to confirm the PCR results are the main problems of this technique ([@b0075]). Nowadays, PCR assays for *Pneumocystis* are commonly used for diagnosis ([@b0080]), even though they are not usually presented clinically but are a lot used in research settings.

Many studies have suggested that BAL is the ideal sample for *Pneumocystis Jirovecii* detection. The sample collection is delicate and requires expensive items and very-well trained specialists, arising the need for alternative, less harmful methods to detect this organism ([@b0095]).

The detection of *Pneumocystis Jirovecii* by PCR is highly sensitive; however, the diagnosis should not rely only on PCR. Thus, the decision of PCP diagnosis should be concluded according to the clinical symptoms, signs, radiological imaging, and advanced microbiology techniques, especially if the PCR result strongly positive ([@b9000]), with which we agree entirely.

5. Conclusion {#s0055}
=============

As revealed in our study, BAL is the ideal sample, considering the significant harmful due to the procedures of collecting the sample. Although *Pneumocystis* RT-PCR has been demonstrated to be more sensitive than commonly used morphologic methods, although RT-PCR & IFAT are expensive methods for *Pneumocystis Jirovecii* detection in countries with limited resources. In lab settings where RT-PCR & IFAT are not available, GMSS staining might be the best option for *Pneumocystis Jirovecii* detection.
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